Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.
about
Use of Reporter Genes in the Generation of Vaccinia Virus-Derived VectorsMoving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic virusesExploring Reovirus Plasticity for Improving Its Use as Oncolytic VirusOncolytic viruses: finally deliveringOncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic ApplicationsModular Three-component Delivery System Facilitates HLA Class I Antigen Presentation and CD8(+) T-cell Activation Against Tumors.Development of dual-activity vectors by co-envelopment of adenovirus and SiRNA in artificial lipid bilayers.An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cellsDefining Effective Combinations of Immune Checkpoint Blockade and Oncolytic VirotherapyPotentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer.Categorization of cancer through genomic complexity could guide research and management strategies.Arming oncolytic viruses to leverage antitumor immunity.Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients.Oncolytic immunotherapy: unlocking the potential of viruses to help target cancerSolid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.Harnessing oncolytic virus-mediated anti-tumor immunityCapitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies.A PTENtial cause for the selectivity of oncolytic viruses?Oncolytic virus and PD-1/PD-L1 blockade combination therapyCAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
P2860
Q26746915-721F2BC7-AF9D-4190-AA6D-B3E36890147BQ26752807-24FD6C20-95E6-4D70-A240-95E6DFDECE2DQ26771799-E74B13C8-CA8E-4AA0-A1DA-06D5C542FD50Q26772039-35168E26-CEF3-40F5-93E6-22558E90F2DDQ26776553-057CE365-B604-40DA-A3B1-2285B05FD552Q30358614-4399AEF9-445B-409A-A5E6-C15A5597ED1DQ34690551-199C93B3-7EA9-47F0-9567-0BAFBE500412Q35893563-CCF958A7-7B7A-42A3-AFDB-E997409DC82BQ36378248-E31AC824-A014-47CB-8C2D-E2D14050B072Q36664213-7313CA18-2348-44EB-A80D-7782D1E1E6B0Q38416477-4699F90F-EFD5-40FD-8301-B1BCF01635F1Q38470166-4131D147-FCC1-4923-B82B-4B7DBFB6E8B8Q39322307-2CDCCAC4-1D04-49C8-8C4A-1555AE4D3EE1Q39437344-0941793D-24DF-470F-864F-752B2CACE9BCQ40043393-1C29AF5B-A535-44AD-8FE2-2745158EE46CQ42176959-D21C8D61-9E72-4E74-828E-01547DB06D19Q50865520-C99801FF-AD48-4D9E-9BC8-80E6D7083096Q50896873-5B4DE764-A4B4-4901-BB91-51CF976F59AAQ57174025-459F598E-D679-4295-B1AA-48656BA0718BQ58572502-9CAF2E5B-5227-4438-9209-6A3BD441D112
P2860
Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.
@en
type
label
Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.
@en
prefLabel
Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.
@en
P2860
P356
P1476
Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.
@en
P2093
Maxine Bauzon
Terry Hermiston
P2860
P356
10.3389/FIMMU.2014.00074
P577
2014-02-24T00:00:00Z